@lycrahelen93
Active 7 months, 1 week ago
After 3months, in our cohort, dual therapy does not seem to add more benefit than anti-CGRP mAbs in monotherapy.
Patients with prior treatment failure or partial efficacy to onabotulinumtoxinA respond to anti-CGRP mAbs. After 3 months, in our cohort, dual therapy does not seem to add more benefit than anti-CGRP mAbs in monotherapy. […] View
Sorry, there was no activity found. Please try a different filter.